Physician profile
Ravi Singh
NPI 1417108317
$471.35
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.11 · 2021: $214 · 2022: $159.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $152.53 | 2021 | |
| Biogen, INC. | $122.84 | 2021-2022 | |
| Livanova USA, INC. | $118.36 | 2019-2021 | |
| Tersera Therapeutics LLC | $20.69 | 2022 | |
| Neurocrine Biosciences, INC. | $16.64 | 2022 | |
| Emd Serono, INC. | $14.86 | 2022 | |
| Neurelis, INC. | $13.34 | 2022 | |
| Mdd US Operations, LLC | $12.09 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.